Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
11.4 EUR | +3.17% | +2.70% | -10.59% |
Mar. 14 | Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 | CI |
Mar. 14 | Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024 |
Sales 2024 * | 12.2M 13.15M | Sales 2025 * | 25.5M 27.49M | Capitalization | 309M 334M |
---|---|---|---|---|---|
Net income 2024 * | -12M -12.94M | Net income 2025 * | -4M -4.31M | EV / Sales 2024 * | 24 x |
Net cash position 2024 * | 16.45M 17.74M | Net cash position 2025 * | 16.2M 17.47M | EV / Sales 2025 * | 11.5 x |
P/E ratio 2024 * |
-21
x | P/E ratio 2025 * |
-55.3
x | Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 43.38% |
Latest transcript on Hyloris Pharmaceuticals SA
1 day | +3.17% | ||
1 week | +2.70% | ||
Current month | -6.94% | ||
1 month | -7.32% | ||
3 months | -10.94% | ||
6 months | -3.39% | ||
Current year | -10.59% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Jacobsen
FOU | Founder | 50 | 11-12-31 |
Stijn van Rompay
FOU | Founder | 48 | 11-12-31 |
Director of Finance/CFO | 53 | 21-09-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carolyn Myers
BRD | Director/Board Member | 66 | 19-12-31 |
James Gale
BRD | Director/Board Member | 74 | 19-12-31 |
Leon van Rompay
BRD | Director/Board Member | 75 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 11.4 | +3.17% | 10 574 |
24-03-27 | 11.05 | -0.45% | 40,107 |
24-03-26 | 11.1 | -1.77% | 3,914 |
24-03-25 | 11.3 | +1.80% | 8,841 |
24-03-22 | 11.1 | 0.00% | 19,438 |
Real-time Euronext Bruxelles, March 28, 2024 at 05:52 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.59% | 335M | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.72% | 210B | |
+1.34% | 210B | |
-6.91% | 201B | |
-3.51% | 157B |